<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02150993</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 12294 FIT-2</org_study_id>
    <nct_id>NCT02150993</nct_id>
  </id_info>
  <brief_title>First-Line Treatment for HIV-2</brief_title>
  <acronym>FIT-2</acronym>
  <official_title>A Randomized, Non-comparative, Phase IIb, Unblinded Trial, Evaluating the Efficacy and Safety of Tenofovir-emtricitabine or Lamivudine Plus Zidovudine, Lopinavir/Ritonavir, or Raltegravir, Among ARV-naïve HIV-2 Infected Adult Patients, in West Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      FIT-2 is a multi-country, phase IIb, randomized, non-comparative study, carried out in West
      Africa (Côte d'Ivoire, Burkina Faso, Senegal, Togo).

      ARV-naïve HIV-2 infected adult patients will be recruited and followed during 96 weeks.

      The objective is to evaluate the efficacy and safety of 3 first-line treatments in HIV-2
      infected adult patients, in West Africa. A treatment will be considered as effective if more
      than 55% of patients in that arm attain &quot;global success&quot; at 96 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main objective

      To determine in treatment-naïve HIV-2 infected patients, with CD4 counts above 200 cells/mm3,
      which of the following three regimens of first line treatment, Tenofovir (TDF), Emtricitabine
      or lamivudine (FTC or 3TC) plus Zidovudine (ZDV); TDF-FTC (3TC) plus Lopinavir/ritonavir (LPV
      / r); or TDF-FTC (3TC) plus raltegravir (RAL), will result in an &quot;global success&quot; rate of &gt;
      55% at week 96.

      Number of participants : 210

      Main outcome :

      The proportion of patients with &quot;global success&quot; at W96, defined by survival with a plasma
      HIV-2 RNA viral load of &lt;50 copies/ml and the non-occurrence of AIDS classified events
      (excluding tuberculosis) and the non-occurrence of severe morbidities non-AIDS-defining
      illness (cardiovascular disease, kidney disease, severe bacterial disease) and a delta of CD4
      depending on the initial CD4 count (CD4 delta &gt; +100cells/mm3 for initial CD4s between 201
      and 500 cells/mm3 or delta ≥0 cells/mm3 for initial CD4s &gt; +500 cells/mm3)

      Inclusion criteria:

        -  Infection by HIV-2 only;

        -  Age &gt; or = 18 years;

        -  Naïve for antiretroviral therapy (including antiretroviral treatment in the context of
           PMTCT except taking a dose of Nevirapine for PMTCT)

        -  CD4 &gt;200 cells/mm3

        -  Resident of the city where the study is held or of city suburbs to facilitate
           participation

        -  Signed informed consent document
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 26, 2016</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The &quot;overall success&quot;</measure>
    <time_frame>96 weeks</time_frame>
    <description>The proportion of patients with &quot;global success&quot; at W96, defined by survival with a plasma HIV-2 RNA viral load of &lt;50 copies/ml and the non-occurrence of AIDS classified events (excluding tuberculosis) and the non-occurrence of severe morbidities non-AIDS-defining illness (cardiovascular disease, kidney disease, severe bacterial disease) and a delta of CD4 depending on the initial CD4 count (CD4 delta&gt; +100cells/mm3 for initial CD4s between 201 and 500 cells/mm3 or delta ≥0 cells/mm3 for initial CD4s &gt; +500 cells/mm3)
A treatment is considered to be effective if the &quot;global success&quot; is &gt; 55 % at 96 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Therapeutic failure</measure>
    <time_frame>24 weeks</time_frame>
    <description>The percentage of patients in &quot;treatment failure&quot; defined by :
death or
a delta ≤0 CD4 cells / mm3 between W2 and W24 (or W48) for patients with baseline CD4 between 201 and 500 cells / mm3 or if % of decrease in CD4 &gt; 20% between W2 and W24 (or W48) for patients with baseline CD4 &gt; 500 cellules/mm3 or
a plasma HIV-2 RNA viral load of &gt; or =50 copies/ml or
the occurrence of an AIDS defining event (excluding tuberculosis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic failure</measure>
    <time_frame>48 weeks</time_frame>
    <description>The percentage of patients in &quot;treatment failure&quot; defined by :
death or
a delta ≤0 CD4 cells / mm3 between W2 and W24 (or W48) for patients with baseline CD4 between 201 and 500 cells / mm3 or if % of decrease in CD4 &gt; 20% between W0 and W24 (or W48) for patients with baseline CD4 &gt; 500 cellules/mm3 or
a plasma HIV-2 RNA viral load of &gt; or = 50 copies/ml or
the occurrence of an AIDS defining event (excluding tuberculosis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and type of severe clinical or biological severe adverse events per arm</measure>
    <time_frame>between Week 0 and Week 96</time_frame>
    <description>Incidence and type of severe clinical or biological severe adverse event (grade 3 or 4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The clinical progression</measure>
    <time_frame>between Week 0 and Week 96</time_frame>
    <description>The incidence of severe morbidity, defined as: AIDS morbidity, non-AIDS cancer, severe non-AIDS bacterial disease, or any disease leading to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The evolution of CD4 counts</measure>
    <time_frame>between Week 0 and Week 96</time_frame>
    <description>Evolution of the absolute and percentage CD4 counts during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The evolution of plasma HIV-2 RNA load</measure>
    <time_frame>between at W0 and W96</time_frame>
    <description>Evolution of the plasma viral load during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The observance of antiretroviral treatment</measure>
    <time_frame>between W0 and W96</time_frame>
    <description>To describe the antiretroviral possession ratio and assessment of compliance by questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The resistance mutations profile</measure>
    <time_frame>Weeks 96</time_frame>
    <description>Description of new resistance mutations profiles in cases of treatment failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The evolution of the HIV-2 DNA titers in PBMC</measure>
    <time_frame>between Week 0 and Week 96</time_frame>
    <description>To describe the evolution the HIV-2 DNA titers in PBMC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The frequency of treatment switches and discontinuations</measure>
    <time_frame>between Week 0 and Week 96</time_frame>
    <description>The frequency of modifications and discontinuations of treatment per arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To model the long-term survival and cost-effectiveness ratio</measure>
    <time_frame>Weeks 96</time_frame>
    <description>The probability of survival and the incremental cost-effectiveness of these three treatment regimens</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>HIV-2 Infection</condition>
  <arm_group>
    <arm_group_label>Arm A : TDF + FTC (or 3TC) + ZDV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenofovir + Emtricitabine or Lamivudine + Zidovudine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TDF+FTC (or 3TC) +LPV/r</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C : TDF +FTC (or 3TC) + RAL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenofovir + Emtricitabine or Lamivudine + Raltegravir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir + Emtricitabine or Lamivudine + Zidovudine</intervention_name>
    <description>TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + ZDV (Zidovudine 300 mg) 1 tb BID (mornings and evenings orally)</description>
    <arm_group_label>Arm A : TDF + FTC (or 3TC) + ZDV</arm_group_label>
    <other_name>TDF+FTC (or 3TC) + ZDV</other_name>
    <other_name>TDF+FTC (or 3TC) + AZT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir</intervention_name>
    <description>TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + Lop/r (Lopinavir/ritonavir lopinavir 200/50 mg) 2 tbs BID (mornings and evenings orally)</description>
    <arm_group_label>TDF+FTC (or 3TC) +LPV/r</arm_group_label>
    <other_name>TDF +FTC (or 3TC) +LPV/r</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir + Emtricitabine or Lamivudine + Raltegravir</intervention_name>
    <description>TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + RAL (Raltegravir 400 mg) 1 tb BID (mornings and evenings orally)</description>
    <arm_group_label>Arm C : TDF +FTC (or 3TC) + RAL</arm_group_label>
    <other_name>TDF +FTC (or 3TC) + RAL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infection by HIV-2 only;

          -  Age &gt; ou = 18 years;

          -  Naïve for antiretroviral therapy (including antiretroviral treatment in the context of
             PMTCT except taking a dose of Nevirapine for PMTCT)

          -  CD4 &gt;200 cells/mm3

          -  Resident of the city where the study is held or of city suburbs to facilitate
             participation

          -  Signed informed consent document

        Exclusion Criteria:

          -  Current participation in any other clinical trial

          -  Presence of opportunistic non-stabilized infections, of any serious or progressive
             disease, or of any clinical signs consistent with severe disease whose diagnosis is
             not yet confirmed, such as fever, weight loss, diarrhea or cough not yet explained
             (non-exhaustive list).

          -  All pathology that leads in daily life to prefer one or the other of the three
             therapeutic regimens for medical reasons or to change the dosages specified in the
             test. This includes (but not limited to):

          -  Hemoglobin ≤ 8 g / dL

          -  Neutrophil count &lt;500 cells/mm3

          -  Renal impairment with creatinine clearance &lt;50mL/mn

          -  Blood platelet &lt;50 000 cells/mm3

          -  Decompensated heart failure

          -  Hepatic failure Severe (TP&lt;50% or cytolysis severe (ALAT&gt; 3x ULN)

          -  Active TB during treatment with rifampicin

          -  Taking drugs that interact with the drugs of the clinical trial (as specified in the
             SPC)

          -  Pregnancy, breastfeeding or planning to become pregnant during study follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Serge P. Eholié, MD, MSc, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service des Maladies Infectieuses et Tropicales, CHU de Treichville, Abidjan, Côte d'Ivoire</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Françoise P. Brun-Vézinet, MD, MSc, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laboratoire de virologie, Hôpital Bichat-Claude Bernard</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Sourô Sanou</name>
      <address>
        <city>Bobo-Dioulasso</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Yalgado Ouedraogo</name>
      <address>
        <city>Ouagadougou</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Prise en Charge et de Formation (CePReF), Association ACONDA</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Médical du Suivi des Donneurs de Sang (Blood Bank Medical Centre)</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIRBA</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>o L'Unité de soins ambulatoires et de conseils (USAC), CHU de Treichville</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses et Tropicales (SMIT), CHU de treichville</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHNU Fann</name>
      <address>
        <city>Dakar</city>
        <country>Senegal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ONG Espoirs Vie Togo (EVT)</name>
      <address>
        <city>Lome</city>
        <country>Togo</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
    <country>Côte D'Ivoire</country>
    <country>Senegal</country>
    <country>Togo</country>
  </location_countries>
  <link>
    <url>http://www.anrs.fr</url>
    <description>sponsor site</description>
  </link>
  <link>
    <url>http://www.mereva.net/</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2014</study_first_submitted>
  <study_first_submitted_qc>May 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2014</study_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Africa</keyword>
  <keyword>Antiretroviral Treatment</keyword>
  <keyword>HIV-2</keyword>
  <keyword>firsts line ART</keyword>
  <keyword>Adults</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

